New Models for Angel Investing in the Life Sciences
There has been a shift over the last several years in the way private “angel” investors have participated in backing life science entrepreneurs and innovation. Changes include the growth of angel networks and investing groups, increased specialization in screening deals and due diligence, the structure of investment deals, the amount invested, the stage of investment, and the types of companies that draw interest from angel investors.
Please join us for a panel discussion about the emerging new model for angel investing. Topics will also include the evolving role of angel investing in the larger funding environment, and the implications for life science investing in Michigan.
Michael W. Henry
Mike Henry has over 20 years of experience in biotechnology business development and is active as an angel investor, board director, startup mentor, and consultant. He served as Vice President, Business Development, at Quest Diagnostics Inc., the world’s leading provider of diagnostic information services. Quest is the parent company of Athena Diagnostics Inc., where Mike served 2004-2013 as Vice President, Business Development, serving on the senior leadership team that sold Athena to Fisher Scientific for $283 million in 2006, and to Quest for $740 million in 2011—6.7X revenue, the highest revenue multiple ever paid for a diagnostics business.
Previously, Mike served as Vice President, Business Development, at Avant Immunotherapeutics Inc., subsequently acquired by Celldex. Prior to Avant, he worked at academic medical centers, serving as Senior Director, Licensing and Ventures, at University of Massachusetts Medical School, and Director, Technology Transfer, at Children’s Hospital of Philadelphia. Prior to CHOP, he served as Manager, New Business Development, at Allelix Inc., Mississauga, Ontario.
Recognized as a National Science Foundation Graduate Fellow as a PhD student at University of California Berkeley, Mike received an MBA and an MS from University of California Berkeley, and a BS from University of Michigan.
John Dahler is a senior financial executive with over 30 years experience providing financial, operational, and managerial expertise for companies ranging in both the private and public sectors in the life sciences, manufacturing, financial, and services industries.
John has served as a financial executive at KPMG, Pillsbury/Grand Metropolitan, Fiskars, Promega, Ambion/Asuragen and Accuri Cytometers. John has successfully led numerous mergers and acquisitions including his role as CFO in the sale of Ambion, Inc. to Applied BioSystems (now Life Technologies) and most recently Accuri Cytometers, Inc. to Becton Dickinson. John has significant knowledge and experience in accounting, finance, mergers and acquisitions, business restructurings, venture led financing, strategic planning, and operational management.
John received his Bachelor of Sciences degree from the University of Wisconsin and has served on several not-for-profit boards. John is certified as both a CPA and CMA.